ALLOX
AI-driven drug discovery platform focused on identifying allosteric sites to support the development of new medicines.
ALLOX is a biotech & life sciences company. It has raised $10.5 million in disclosed funding. Its latest round was a Seed of $10.5 million in October 2026.
Overview
ALLOX operates a drug discovery platform focused on identifying and targeting allosteric sites on proteins [0]. The company utilizes a high-throughput experimental approach combined with artificial intelligence to map protein function and discover new drug targets [0]. By combining computational biology with generative genomics, ALLOX aims to accelerate the discovery of therapeutics for various medical conditions [0]. ALLOX operates a business model centered on advancing its own internal pipeline while simultaneously establishing partnerships with pharmaceutical and biotech companies [0]. Based in Barcelona, the startup secured $10.5 million in seed funding in a round led by Asabys, with additional participation from CDTI and ICF [0]. The company is currently scaling its discovery platform and expanding its research capabilities [0]. ALLOX’s multidisciplinary team integrates expertise in bioinformatics, molecular biology, and deep learning to decipher allosteric regulation, aiming to solve complex problems in drug discovery [0].
Funding
Total disclosed: $10.5M across 1 round. Computed only from sourced rounds.
Investors
Questions and answers
What does ALLOX do?
AI-driven drug discovery platform focused on identifying allosteric sites to support the development of new medicines.
How much has ALLOX raised?
ALLOX has raised $10.5 million in disclosed funding across 1 round tracked by OSH.
Who has invested in ALLOX?
Investors in ALLOX include Asabys Partners, CDTI, and Institut Català de Finances.
Sources
- 1.ALLOX closes $10.5M seed financing to scale drug discovery platform — Tech.eu, Oct 29, 2026
- 2.ALLOX · Official
- 3.ALLOX · Official
- 4.ALLOX · Official
- 5.ALLOX · Official